Golidocitinib in China: a focused review for relapsed PTCL

Golidocitinib is a selective JAK1 inhibitor taken by mouth. It is a medicine for a defined lymphoma population, not a general treatment for all lymphomas.

China’s NMPA describes conditional marketing approval. This regulatory status and its specific indication should be checked again during a hospital review.

The announced Chinese indication is single-agent golidocitinib for adults with relapsed or refractory peripheral T-cell lymphoma after at least one line of systemic treatment. PTCL contains several subtypes, and specialist pathology review can change the diagnosis or treatment choice.

A matching diagnosis and treatment history are starting points only. Blood counts, infections, other illnesses and the current product label matter to an individual decision.

• Original pathology diagnosis, subtype, immunohistochemistry and any expert re-review.
• Dated prior systemic treatments, response, relapse or refractory status.
• Recent imaging, blood counts, liver and kidney tests, and infection history.
• Current medicines, symptoms, performance status and treating hematologist’s summary.

Send existing records for specialist review first. Ask whether the pathology needs re-review, whether additional tests are required, how medicine supply and monitoring work, and whether treatment can be managed near home. Do not book travel on the basis of the drug name alone.

A hematologist verifies PTCL subtype and prior therapy, reviews baseline safety, explains oral treatment and sets blood-count, infection and response monitoring. Treatment duration and visit frequency depend on response and toxicity.

Request separate estimates for pathology review, consultations, drug supply, laboratory monitoring, imaging, adverse-event care and follow-up. Add travel, accommodation and coordination to see the total commitment.

The JACKPOT8 phase 2 study reported substantial grade 3–4 treatment-related adverse events, particularly reduced blood counts, and serious adverse events. The specialist should discuss infection risk, monitoring, dose changes and when urgent help is needed.

JACKPOT8 was a single-arm study. Its results cannot establish a direct comparison with another treatment or predict one patient’s outcome. Conditional approval does not remove the need for careful review.

Depending on PTCL subtype, prior therapy and fitness, a hematologist may discuss other systemic medicines, transplant or cellular approaches where relevant, clinical trials and supportive care. The right comparison is individual.

We can assemble pathology and treatment records, coordinate the hospital enquiry and clarify practical arrangements. The hospital decides diagnosis, medicine selection and monitoring; MedRelay does not promise access or results.